EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of ABBV ‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

Frank Buttgereit iD, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann und 2 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43266 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Frank Buttgereit und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Uni…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Adalimumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks. ABBV‐154, an antibody‐drug conjugate, is made up of adalimumab linked to a glucocorticoid receptor modulator. This phase 2b study evaluated the efficacy and safety of ABBV‐154 in patients with moderately to severely active RA receiving background methotrexate with inadequate response to at least one prior b/tsDMARD.

Methods

Patients were randomized 1:1:1:1:1 to subcutaneous ABBV‐154 40, 150, or 340 mg every other week; 340 mg every 4 weeks; or placebo. The primary endpoint was achieving 50% improvement in the American College of Rheumatology response criteria (ACR50) at week 12; secondary endpoints included achieving the ACR20 and ACR70 criteria. Treatment‐emergent adverse events (TEAEs) were monitored. Clinical development of ABBV‐154 was discontinued; the study was terminated early.

Results

Overall, 472 patients were treated. At week 12, more patients achieved ACR50 (primary endpoint) with ABBV‐154 (25.5%–44.4% across dose groups) versus placebo (6.3%; all P < 0.001). ACR20 response rates were higher in all ABBV‐154 treatment groups versus placebo ( P < 0.001). Most ABBV‐154 groups achieved the other secondary endpoints. For all ABBV‐154 doses, TEAEs rates through week 12 were similar to placebo. Ten serious infection TEAEs occurred in the ABBV‐154 groups.

Conclusion

ABBV‐154 demonstrated superior efficacy over placebo in patients with RA and inadequate response to prior b/tsDMARDs. TEAE rates in all ABBV‐154 arms were comparable with placebo. These findings provide useful insights into the design of new antibody‐drug conjugates for RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsAdalimumabAntibodies, Monoclonal, HumanizedImmunoconjugatesHumansMaleFemaleMiddle AgedTreatment OutcomeAdultAgedDouble-Blind MethodMethotrexate

Substanzen

Antirheumatic AgentsAdalimumabMethotrexateAntibodies, Monoclonal, HumanizedImmunoconjugates

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Deutsches Rheumaforschungszentrum, Berlin, Ger…
  • SouthWest Arthritis Research Group, Mesquite, Texas.
  • Altoona Arthritis and Osteoporosis Center, Altoona Center for Clinical Research, Duncansville, Pennsylvania.
  • Department of Rheumatology, Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary.
  • Department of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School Hospital, Nankoku, Japan.
  • Servicio de Reumatología, Hospital Universitario de Valme, Valme, Spain.

ORCID-Profile: Frank Buttgereit

Zitieren

APA

Buttgereit, F., Singhal, A., Kivitz, A., Drescher, E., Taniguchi, Y., Pérez, R. M., Anderson, J., D'Cunha, R., Zhao, W., DeVogel, N., Parmentier, J., Christmann, R., Arikan, D., & Amital, H. (2025). Efficacy and Safety of ABBV ‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.43266

Vancouver

Buttgereit F, Singhal A, Kivitz A, Drescher E, Taniguchi Y, Pérez RM, et al. Efficacy and Safety of ABBV ‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial. Arthritis & Rheumatology. 2025. doi:10.1002/art.43266

BibTeX
@article{Buttgereit2025,
  author = {Buttgereit, Frank and Singhal, Atul and Kivitz, Alan and Drescher, Edit and Taniguchi, Yoshinori and Pérez, Rosalía Martínez and Anderson, Jaclyn and D'Cunha, Ronilda and Zhao, Weihan and DeVogel, Nicholas and Parmentier, Julie and Christmann, Romy and Arikan, Dilek and Amital, Howard},
  title = {Efficacy and Safety of ABBV ‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43266}
}
Kostenlos starten →